Sign up & Download
Sign in

CRK7 modifies the MAPK pathway and influences the response to endocrine therapy.

by Elizabeth Iorns, Sanne R Martens-de Kemp, Christopher J Lord, Alan Ashworth
Carcinogenesis ()

Abstract

Endocrine therapies, which inhibit estrogen receptor (ER)alpha signaling, are the most common and effective treatment for ERalpha-positive breast cancer. However, the use of these agents is limited by the frequent development of resistance. The cyclin-dependent kinase family member CRK7 (aka CRKRS) was identified from an RNA interference screen for modifiers of tamoxifen sensitivity. Here, we demonstrate that silencing of CRK7 not only causes resistance to tamoxifen but also leads to resistance to additional endocrine therapies including ICI 182780 and estrogen deprivation, a model of aromatase inhibition. We show that CRK7 silencing activates the mitogen-activated protein kinase (MAPK)-signaling pathway, which causes a loss of ER dependence, resulting in endocrine therapy resistance. This study identifies a novel role for CRK7 in MAPK regulation and resistance to estrogen signaling inhibitors.

Cite this document (BETA)

Authors on Mendeley

Readership Statistics

7 Readers on Mendeley
by Discipline
 
 
by Academic Status
 
29% Student (Master)
 
29% Ph.D. Student
 
14% Researcher (at a non-Academic Institution)
by Country
 
14% Netherlands
 
14% United States

Sign up today - FREE

Mendeley saves you time finding and organizing research. Learn more

  • All your research in one place
  • Add and import papers easily
  • Access it anywhere, anytime

Start using Mendeley in seconds!

Already have an account? Sign in